Generic Tobi Podhaler
Patents are currently in place that prevent a company from making a generic Tobi Podhaler (tobramycin inhalation powder). However, this may change after the first patent for the drug expires in June 2021. Although tobramycin is sometimes referred to as the generic name for Tobi Podhaler, it is simply the active ingredient in the drug.
Tobi® Podhaler™ (tobramycin inhalation powder) is a prescription medication used to treat people with cystic fibrosis who have an infection with the bacteria Pseudomonas aeruginosa. It contains tobramycin, an aminoglycoside antibiotic.
Tobi Podhaler is made by Novartis Pharmaceuticals Corporation. It is currently protected by patents that prevent any generic versions from being manufactured in the United States.
The first patent for Tobi Podhaler is set to expire in June 2021. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or delay this exclusivity period, including such things as lawsuits or other patents for new Tobi Podhaler uses. Once the patents expire, there may be several companies that manufacture a generic version of this drug.
No -- tobramycin is the active ingredient in Tobi Podhaler, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.